Real-World Evidence for GLP-1 Obesity Treatment Among Patients without Diabetes + Panel Discussion on GLP-1s

This presentation will review the indications for GLP-1 therapies to treat obesity in patients without diabetes. Use of these products is associated with side effects and adverse events, and improvements in clinical outcomes and medical cost offsets are not observed through medical claims analysis within two years of initiation. Learn from experts who discuss the pros and cons of GLP-1 medications for patients struggling with weight management.

Participants are expected to watch the video, reflect on its content, and complete the CEU self-assessment and CEU evaluation. Only upon completing this process will a participant's continuing education certificate be generated. The estimated time a learner will need to complete this self-study activity is 45 minutes. 

This activity is approved for continuing education for physicians, nurses, and dietitians. 

The George Washington University School of Medicine and Health Sciences designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. 

Objectives: 

• Describe the persistence to GLP-1 therapies to treat obesity among a real-world cohort of patients without diabetes.
• Understand real-world impact of GLP-1 therapies on clinical outcomes and medical spending.
• Examine considerations related to use of GLP-1 medications for weight management.

Requirements for successful completion: Participants will be awarded contact hours commensurate with participation after completion of the post-test with a score of 70% or higher.